The use of extended-release tolperisone hydrochloride in a patient with ankylosing spondylitis and post-Covid syndrome

SARS-CoV-2 infection can induce or worsen joint and muscle pain both in the acute phase and after disappearance of respiratory symptoms of COVID-19. The condition of patients with immune inflammatory diseases who have a history of recent COVID-19 should be assessed carefully, since worsening arthralgia and myalgia not always indicate an exacerbation of rheumatic disease. The mechanisms of pain induced by viral infection remain indecisive, as well as approaches to their treatment. The authors report tolperisone hydrochloride extended release administration to a patient with ankylosing spondylitis and post-Covid syndrome. Treatment with centrally acting muscle relaxant and non-steroidal anti-inflammatory drug rapidly improved pain in the cervical, thoracic and sacroiliac spine, alleviated night pain and morning stiffness, and increased the range of motion in the cervical and lumbar spine. The effect of treatment persisted within a month after its completion.

Key words

Ankylosing spondylitis, post-Covid syndrome, tolperisone hydrochloride extended release, myalgia, arthralgia.